Cover Image
市場調查報告書

疫苗市場概要:病的結束

Vaccines: The End of Illness

出版商 Insight Pharma Reports 商品編碼 298556
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
疫苗市場概要:病的結束 Vaccines: The End of Illness
出版日期: 2014年11月30日 內容資訊: 英文 164 Pages
簡介

本報告提供疫苗市場相關調查、疫苗的歷史、現狀及技術的分析,再加上主要企業簡介、疫苗的未來的方向性,及專家的調查採訪等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 多的疫苗技術

  • 疫苗生產:雞蛋 vs.細胞培養
  • 細胞株的選擇
  • 傳統疫苗
  • 佐劑
  • 奈米粒子為基礎的疫苗
  • DNA疫苗
  • 疫苗促進的T細胞活躍
  • 樹狀細胞

第3章 疫苗的目標

  • 感染疾病
  • 癌症疫苗

第4章 大型製藥企業的疫苗

  • AstraZenica (Medimmune)
  • Baxter
  • GSK
  • J&J (Crucel)
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

第5章 小規模製藥企業的疫苗

第6章 法規的課題

  • 困難的路程
  • 目前法規情形

第7章 未來的疫苗技術

  • 運送和儲存的課題
  • 乾燥疫苗技術:
  • 對尖峰時段的準備?
  • 萬能疫苗
  • 生物恐怖行動:全世界的威脅?
  • 智慧財產權的均衡
  • 疫苗的明亮未來

第8章 疫苗技術相關意見的調查:透過產業成員

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

New to Insight Pharma Reports is Vaccines: The End of Illness. This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

Specific Highlights Include:

  • This report profiles some of the major pharma companies involved in vaccine R&D and a number of biotech companies developing new vaccine products and technologies - including 35 small pharma companies and 8 big pharma companies profiled
  • The logistics and management of the vaccine industry are increasingly based on partnerships between the private sector (pharma and biotech companies), government agencies (WHO) and large non-profits (such as the Gates Foundation).
  • An assessment of the future directions of vaccines as innovative medical therapies for a wide range of diseases.
  • Explores conditions not normally thought to be in purview of vaccination, including substance abuse and neurological disorders such as Alzheimer's disease and Parkinson's disease.
  • Survey of industry experts concerning the political economic and technological future of vaccine technology.
  • Over 20 pages of pipeline and clinical trial data specific to vaccine targets
  • Over 30 pages of pipeline and clinical trial data specific to cancer vaccines

Table of Contents

Executive Summary

CHAPTER 1 Introduction

  • 1.1 The History of Vaccination
    • 1.1.1 Ancient
    • 1.1.2 18th Century
    • 1.1.3 19th Century
    • 1.1.3.1 Koch and Pasteur
    • 1.1.3.2 Coley's Toxins
    • 1.1.4 Mid 20th Century
  • 1.2 Vaccines in the Doldrums: Late 20th century
    • 1.2.1 Liability Issues
    • 1.2.2 Vaccine Denialism
  • 1.3 The Current State of Vaccine Technology, 2014
    • 1.3.1 WHO
    • 1.3.2 Behemoth Players: Bill and Melinda Gates Foundation
    • 1.3.3 Big Pharma Jumps In

CHAPTER 2 A Cornucopia of Vaccine Technologies

  • 2.1 Viral Vaccine Production: Eggs Versus Cell Culture
  • 2.2 Cell Line Options
  • 2.3 Conventional Vaccines
  • 2.4 Adjuvants
  • 2.5 Nanoparticles-Based Vaccines
  • 2.6 DNA Vaccines
  • 2.7 Vaccines Driving T-Cell Activation
  • 2.8 Dendritic Cells

CHAPTER 3 Vaccine Targets

  • 3.1 Intectious Diseases
    • 3.1.1 Influenza
    • 3.1.2 Herpes Simplex
    • 3.1.3 C. Difficile
    • 3.1.4 HIV
    • 5.1.5 Pneumococcal Pneumonia
    • 3.1.6 Typhoid
    • 3.1.7 Candida
    • 3.1.8 Rabies
    • 3.1.9 Rptavoris
    • 3.1.10 Polio
    • 3.1.11 Malaria
    • 3.1.12 Other Parasitic Diseases
    • 3.1.13 Smallpox
    • 3.1.14 Cholera
    • 3.1.15 Mumps
    • 3.1.16 Diphtheria
  • 3.2 Cancer Vaccines
    • 3.2.1 Human Papilloma Virus
    • 3.2.2 Breast Cancer
    • 3.2.3 Pancreatic Cancer
    • 3.2.4 Renal Cell Carcinoma
    • 3.2.5 Melanoma: Dendritic Cells
    • 3.2.6 Prostate Cancer

CHAPTER 4 Big Pharma Vaccinology

  • 4.1 AstraZeneca (Medimmune)
  • 4.2 Baxter
  • 4.3 GSDK Pharma4.4
  • 4.4 J&J (Crucell)
  • 4.5 Merck
  • 4.6 Novartis
  • 4.7 Pfizer
  • 4.8 Sanofi

CHAPTER 5 Small Pharma Vaccines

  • 5.1 AC Immune
  • 5.2 Aeras
  • 5.3 AlphaVax
  • 5.5 Asthellas Pharma Inc.
  • 5.6 Bavarian Nordic
  • 5.7 BiondVax Pharmaceuticals
  • 5.8 Brassch Biotech LLC
  • 5.9 Celldex Therapeutics
  • 5.10 ChronTech Pharma
  • 5.11 Emergent BioSolution Inc
  • 5.12 EpiVax
  • 5.13 GenVec
  • 5.14 GeoVax
  • 5.15 Genocia Biosclences
  • 5.16 Immune Targeting Systems
  • 5.17 Indian Immunologicals Limited
  • 5.18 Inovio
  • 5.19 Inviragen
  • 5.20 Juvaris Biotherapeutics
  • 5.21 Medicago
  • 5.22 Mymetics Corporation
  • 5.23 NovaRx
  • 5.24 Novavax, Inc.
  • 5.25 Nuron
  • 5.26 OPKO Health
  • 5.27 Profectus Biosclence Inc
  • 5.28 SinovacBiotech Ltd
  • 5.29 Sorrento Therapeutics, Inc.
  • 5.30 Tapimmune
  • 5.31 Valneva
  • 5.32 Vaxinnate
  • 5.33 VaxLiant
  • 5.34 VBI Vaccines
  • 5.35 Vical

CHAPTER 6 Regulatory Issues

  • 6.1 A Bumpy Road
  • 6.2 Current Regulatory Status

CHAPTER 7 The Future of Vaccine Technology

  • 7.1 Challenges In Delivery And Storage
  • 7.2 Dry Vaccine Technology: Ready For Prime Time
  • 7.3 A Universal Vaccine
  • 7.4 Outlandish Targets
    • 7.4.1 Drug Abuse
    • 7.4.2 Obesity
    • 7.4.3 Smoking
    • 7.4.4 Alcoholism
    • 7.4.5 Alzheimer's Disease
    • 7.4.6 Parkinson's Disease
  • 7.5 Bioterrorism: A Global Threat
  • 7.6 Intellectual Property in the Balance
  • 7.7 A bright Future For Vaccines

CHAPTER 8 Survey of Opinion Concerning Vaccine Technology by Members of the Industry

About Cambridge Healthtech Institute

FIGURES

    Figure 1.1: Overall Decline in Worldwide Death Rates
  • Figure 2.5: Application of Nano-Sized Delivery Systems
  • Figure 5.11: Emergent's ADAPTIR Design Technology for Antibody Therapeutics
  • Figure 5.15: Genocea Technology for Screening Candidate Vaccines Components
  • Figure 6.2: Development of Anti-cancer Vaccine Products and the Regulatory Guidance Throughout the Process
  • Figure 8.1: Makeup of the Participants in the Survey
  • Figure 8.2: Breakdown of Opinions of the Industrial Commitment of Resources
  • Figure 8.3: How Should the Industry Focus its R&D Efforts in Vaccine Technology?
  • Figure 8.4: What are the Most Promising Cancer Vaccine Targets?
  • Figure 8.5: How Seriously are the Federal Governmental Bodies Committed to Vaccine Technology?
  • Figure 8.6: State and Local Governmental Support for R&D. How Does it Stack Up?
  • Figure 8.7: The Softest Cancer Vaccine Target
  • Figure 8.8: Where is Bioprocessing of Vaccines Headed?
  • Figure 8.9: Why Would a Vaccine Development Program be Vetoed?
  • Figure 8.10: The Fallout from Vaccine Denialism
  • Figure 8.11: Where is Bioprocessing of Vaccines Headed?
  • Figure 8.12: Cancer Vaccines: Still a Long Ways Off
  • Figure 8.13: AIDS Vaccines: Further Down the Road than Cancer Vaccines?
  • Figure 8.14: The Road Ahead: Daunting Challenges
  • Figure 8.15: Is Regulatory Control of Vaccines a Problem?
  • Figure 8.16: How Does the Industry Feel About Vaccines as a Barrier to Terroristic Threats?
  • Figure 8.17: When Vaccines Fail
  • Figure 8.18: Bioinformatics: A Pathway to Innovative Vaccine Antigens
  • Figure 8.19: Counteracting Vaccine Denialism
  • Figure 8.20: Opinions on the Rise of Therapeutic Vaccines
  • Figure 8.21: The Future of Oral Vaccines
  • Figure 8.22: Vaccine Technology in the Third World
  • Figure 8.23: Vaccines and the Battle Against Hepatitis C
  • Figure 8.24: Academic/Industrial Partnerships: Do They Have a Future?
  • Figure 8.25: Alternative Pathways Toward Speeding Vaccine Development
  • Figure 8.26: A New Look at DNY Vaccines

TABLES

    Table 2.2: Anti-Viral Vero Cell-Based Vaccines
  • Table 3.1: Vaccines: Clinical Trials and Pipeline Data
  • Table 3.2: Cancer Vaccines: Clinical Trials and Pipeline Data

Back to Top